Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant trivalent poliomyelitis vaccine
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant trivalent poliomyelitis vaccine is a virus-like particle (VLP) vaccine candidate developed by Sinovac Biotech for the prevention of poliomyelitis. The vaccine is produced using a recombinant baculovirus expression system in a rhabdovirus-negative Spodoptera frugiperda (Sf-RVN) insect cell line. It contains VLPs representing poliovirus serotypes 1, 2, and 3, which are structurally similar to the native virus but lack the viral genome, rendering them non-infectious. This recombinant approach is designed to eliminate the risks associated with live-attenuated vaccines, such as vaccine-associated paralytic poliomyelitis (VAPP) and circulating vaccine-derived polioviruses (cVDPV), while providing a safer and more scalable manufacturing process compared to traditional inactivated polio vaccines (IPV).
- Other names
- VLP-PolioSf-RVN cell-derived polio vaccinerecombinant trivalent VLP polio vaccine
Beyond the preview
Go deeper on recombinant trivalent poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant trivalent poliomyelitis vaccine.